Neurogene Ownership | Who Owns Neurogene?
Neurogene Ownership Summary
Neurogene is owned by 6.86% institutional investors, 8.54% insiders, and 84.59% retail investors. Samsara biocapital is the largest institutional shareholder, holding 8.16% of NGNE shares.
NGNE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Neurogene | 6.86% | 8.54% | 84.59% |
| Sector | Healthcare Stocks | 232.86% | 10.65% | -143.51% |
| Industry | Biotech Stocks | 382.13% | 10.41% | -292.54% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Samsara biocapital | 1.72M | 8.16% | $29.76M |
| Rtw investments, lp | 1.36M | 6.47% | $23.61M |
| Redmile group | 1.30M | 6.17% | $22.51M |
| Casdin capital | 1.30M | 6.15% | $22.45M |
| Ecor1 capital | 1.27M | 6.04% | $22.03M |
| Baker bros. advisors lp | 991.69K | 4.71% | $17.19M |
| Blackrock funding, inc. /de | 945.58K | 4.47% | $19.48M |
| Jennison associates | 527.68K | 3.41% | $10.64M |
| Toronto dominion bank | 681.34K | 3.24% | $11.81M |
| Vanguard group | 656.57K | 3.10% | $13.53M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Samsara biocapital | 1.72M | 3.89% | $29.76M |
| Great point partners | 446.81K | 3.19% | $7.74M |
| Redmile group | 1.30M | 2.19% | $22.51M |
| Casdin capital | 1.30M | 1.87% | $22.45M |
| Ecor1 capital | 1.27M | 1.06% | $22.03M |
| Octagon capital advisors lp | 252.00K | 0.66% | $4.37M |
| Rtw investments, lp | 1.36M | 0.29% | $23.61M |
| Arrowmark colorado | 595.84K | 0.19% | $10.33M |
| Dafna capital management | 30.38K | 0.13% | $526.40K |
| Baker bros. advisors lp | 991.69K | 0.12% | $17.19M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Goldman sachs group | 162.02K | 0.00% | 89.22K |
| Vanguard fiduciary trust | 69.71K | 0.00% | 69.71K |
| Vanguard group | 656.57K | 0.00% | 51.96K |
| Trexquant investment lp | 39.48K | 0.01% | 39.48K |
| Exoduspoint capital management, lp | 32.52K | 0.01% | 32.52K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Deerfield management company, l.p. (series c) | - | - | -446.88K |
| Commodore capital lp | - | - | -427.87K |
| Fmr | 115.55K | 0.00% | -352.93K |
| Price t rowe associates inc /md/ | - | - | -123.29K |
| Deep track capital, lp | - | - | -116.66K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard fiduciary trust | 69.71K | 0.00% | 69.71K | $1.41M |
| Trexquant investment lp | 39.48K | 0.01% | 39.48K | $684.24K |
| Exoduspoint capital management, lp | 32.52K | 0.01% | 32.52K | $563.59K |
| Quadrature capital | 16.83K | 0.00% | 16.83K | $291.97K |
| Renaissance | 14.00K | 0.00% | 14.00K | $288.40K |
Sold Out
| Holder | Change |
|---|---|
| Twin peaks wealth advisors | -5.00 |
| Raymond james financial | -8.00 |
| Corecap advisors | -11.00 |
| Coldstream capital management | -20.00 |
| Signaturefd | -22.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 17 | -80.90% | 1,452,749 | -90.50% | 6 | 0.13% | 7 | -83.33% | 8 | -68.00% |
| Sep 30, 2025 | 26 | -67.50% | 1,140,405 | -92.30% | 5 | 0.11% | 13 | -64.86% | 7 | -74.07% |
| Jun 30, 2025 | 83 | -3.49% | 15,385,506 | 2.02% | 73 | 1.42% | 39 | -11.36% | 27 | 17.39% |
| Mar 31, 2025 | 88 | -3.30% | 16,456,922 | 3.74% | 78 | 0.90% | 45 | -22.41% | 23 | 43.75% |
| Dec 31, 2024 | 92 | 8.24% | 16,089,357 | 16.19% | 94 | 1.42% | 58 | 31.82% | 17 | -22.73% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 06, 2026 | Cvijic Christine Mikail | President and CFO | Sell | $155.69K |
| May 06, 2026 | Cvijic Christine Mikail | President and CFO | Sell | $144.35K |
| Mar 26, 2026 | Cvijic Christine Mikail | President and CFO | Sell | $55.32K |
| Mar 26, 2026 | McMinn Rachel | Chief Executive Officer | Sell | $74.00K |
| Mar 26, 2026 | Jordan Julie | Chief Medical Officer | Sell | $18.13K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | 2 |
| 2026 Q1 | - | 10 |
| 2025 Q2 | - | 1 |
| 2025 Q1 | - | 1 |
| 2024 Q4 | 6 | - |
NGNE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools